Severe combined immunodeficiency
Drug research and approvals for severe combined immunodeficiency: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 11 studies of severe combined immunodeficiency are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 2 approved and 7 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 11
- Trials authorized in Canada: 0
- FDA orphan approvals: 2
- EU medicines: 1
- Targeting Real World Usage In Stroke TreatmentNCT07474935 · Not reported · Phenox GmbH · starts Jan 29, 2026
- Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune…NCT07284641 · Phase 2 · Paul Szabolcs · starts May 4, 2026
- The Experience of Screening for SCIDNCT05651113 · Not reported · King's College London · starts Nov 9, 2022
- Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector…NCT05071222 · Phase 1 / Phase 2 · Assistance Publique - Hôpitaux de Paris · starts Jul 19, 2023
- Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RICNCT04528355 · Not reported · Paul Szabolcs · starts Aug 20, 2020
- Autologous Gene Therapy for Artemis-Deficient SCIDNCT03538899 · Phase 1 / Phase 2 · University of California, San Francisco · starts May 31, 2018
- Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan ConditioningNCT03311503 · Phase 1 / Phase 2 · David Williams · starts Feb 26, 2018
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTNCT01962415 · Phase 2 · Paul Szabolcs · starts Feb 4, 2014
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined…NCT01306019 · Phase 1 / Phase 2 · National Institute of Allergy and Infectious Diseases (NIAID) · starts Sep 25, 2012
Approved 2
- Elapegademase2'-deoxyadenosine hydrolytic enzyme
- Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for…ADA exogenous gene
Phase 3 1
- Pegademase bovine2'-deoxyadenosine hydrolytic enzyme
Phase 2 7
- BusulfanDNA inhibitor
- AlemtuzumabCAMPATH-1 antigen inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- Simoladagene autotemcel
Phase 1 or earlier 5
- Fludarabine
- ThiotepaDNA inhibitor
- ZidovudineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- BriquilimabStem cell growth factor receptor inhibitor
How its trials ended
72 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 16 whose ending is known, 38% met their primary endpoint, 0% missed it and 63% stopped early.
- Ongoing2738%
- Completed, result not reported2332%
- Met its primary endpoint68%
- Stopped: other or unclear68%
- Status unknown68%
- Stopped: enrollment or feasibility34%
- Stopped: lack of efficacy11%
| Oct 5, 2018 | RevcoviTreatment of Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID). | Chiesi USA Inc. | Approved |
| Mar 21, 1990 | AdagenFor enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency. | Sigma-tau Pharmaceuticals, Inc. | Approved |
| May 3, 2026 | Autologous CD3delta severe combined immune deficiency…Treatment of severe combined immunodeficiency (SCID) | University of California, Los Angeles | Designated |
| Sep 17, 2024 | Autologous CD34+ cells transduced with a lentiviral vector…Treatment of severe combined immunodeficiency (SCID) | Videja B.V. | Designated |
| Jun 20, 2023 | Autologous CD34+ hematopoietic stem and progenitor cells…Treatment of patients with Artemis-deficient Severe Combined Immunodeficiency | Morton J Cowan, M.D. | Designated |
| Sep 18, 2020 | Mobilized peripheral blood-derived autologous CD34+…Treatment of severe combined immunodeficiency | Mustang Bio, Inc. | Designated |
| Aug 31, 2020 | Firolimogene autotemcelTreatment X-linked severe combined immunodeficiency. | Mustang Bio, Inc. | Designated |
| Oct 21, 2014 | Autologous bone marrow CD34+ cells transduced ex vivo with…Treatment of adenosine deaminase deficient severe combined immunodeficiency | Donald B. Kohn, M.D. | Designated |
| Aug 26, 2009 | Autologus CD34+ cells transfected with retroviral vector…Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency. | Fondazione Telethon ETS | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| May 26, 2016 | StrimvelisAutologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence · orphan | Fondazione Telethon ETS | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA